Profile data is unavailable for this security.
About the company
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.
- Revenue in USD (TTM)0.00
- Net income in USD-59.50m
- Incorporated2015
- Employees81.00
- LocationConnect Biopharma Holdings Ltd12265 El Camino Real, Suite 350SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 727-1040
- Websitehttps://www.connectbiopharm.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 91.61m | 47.00 | -- | 2.29 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 91.69m | 53.00 | -- | 3.05 | -- | 13.06 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Annovis Bio Inc | 0.00 | -47.53m | 91.94m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Eton Pharmaceuticals Inc | 34.30m | 913.00k | 92.23m | 30.00 | 106.12 | 5.95 | 49.77 | 2.69 | 0.0338 | 0.0338 | 1.33 | 0.6031 | 1.25 | 8.41 | 9.64 | 1,143,467.00 | 3.34 | -46.22 | 5.72 | -58.20 | 66.24 | 72.16 | 2.66 | -76.86 | 1.43 | -- | 0.2447 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 92.64m | 35.00 | 410.98 | 365.90 | -- | 37.15 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 4.70m | -79.58m | 92.92m | 66.00 | -- | -- | -- | 19.77 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 93.85m | 15.00 | 9.29 | 0.5617 | 8.98 | 139.25 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 93.95m | 50.00 | -- | -- | -- | 93.06 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -53.37m | 96.04m | 54.00 | -- | 1.36 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Assertio Holdings Inc | 142.05m | -332.97m | 97.03m | 53.00 | -- | 0.7214 | -- | 0.683 | -3.95 | -3.95 | 1.66 | 1.41 | 0.4081 | 1.19 | 3.19 | 2,680,208.00 | -95.65 | -21.51 | -130.77 | -32.05 | 76.96 | 88.68 | -234.40 | -62.10 | 1.45 | -- | 0.2231 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Athira Pharma Inc | 0.00 | -116.19m | 97.35m | 65.00 | -- | 0.912 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 97.53m | 81.00 | -- | 1.01 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Relmada Therapeutics Inc | 0.00 | -94.30m | 97.76m | 20.00 | -- | 1.36 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| SCYNEXIS Inc | 140.39m | 101.33m | 100.87m | 29.00 | 1.33 | 1.36 | -- | 0.7185 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Yubo International Biotech Ltd | 604.68k | -1.20m | 101.84m | 18.00 | -- | -- | -- | 168.41 | -0.01 | -0.01 | 0.005 | -0.0154 | 0.3012 | 0.6912 | 9.19 | 33,593.33 | -59.52 | -- | -- | -- | 69.32 | -- | -197.64 | -- | 0.1504 | -3,143.97 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
Data as of May 22 2024. Currency figures normalised to Connect Biopharma Holdings Ltd's reporting currency: US Dollar USD
7.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Mar 2024 | 2.06m | 3.74% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 1.04m | 1.89% |
| UBS O'Connor LLCas of 31 Mar 2024 | 510.70k | 0.93% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 239.90k | 0.44% |
| Andbank Wealth Management SGIIC SAUas of 30 Jun 2023 | 30.00k | 0.05% |
| Geode Capital Management LLCas of 31 Mar 2024 | 27.96k | 0.05% |
| Commonwealth Equity Services LLCas of 31 Mar 2024 | 20.00k | 0.04% |
| Keudell/Morrison Wealth Managementas of 31 Mar 2024 | 19.70k | 0.04% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 16.52k | 0.03% |
| Two Sigma Investments LPas of 31 Mar 2024 | 10.81k | 0.02% |
More ▼
Data from 31 Jan 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
